News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Sep 4, 2013

  Insmed to Participate in the Stifel Healthcare Conference 2013
• Aug 7, 2013

  Insmed to Participate in August Investor Conferences
• Aug 6, 2013

  Insmed Reports Second Quarter Financial Results
• Jul 31, 2013

  Insmed to Host Second Quarter 2013 Financial Results Conference Call on Tuesday, August 6, 2013
• Jul 29, 2013

  Insmed Appoints Christine Pellizzari as General Counsel and Corporate Secretary
• Jul 22, 2013

  Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
• Jul 17, 2013

  Insmed Announces Pricing of Public Offering of Common Stock
• Jul 15, 2013

  Insmed Announces Proposed Public Offering of Common Stock
• Jul 8, 2013

  Insmed to Present at the 8th Annual JMP Securities Healthcare Conference
• Jul 1, 2013

  ARIKACE Meets Primary Endpoint of Non-Inferiority to TOBI in Phase 3 Clinical Trial in Europe and Canada to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients

  ARIKACE Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. FDA for the Treatment of Non-Tuberculous Mycobacteria Lung Infections

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download